Evoke Pharma and EVERSANA Launch Social Media Campaign for

Evoke is dedicated to assembly sufferers on-line, the place they search for solutions New marketing campaign leverages Facebook to fulfill vital unmet want for training and neighborhood SOLANA BEACH, Calif. and CHICAGO, May 27, 2021 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical firm centered on remedies for gastrointestinal (GI) illnesses, and EVERSANA™, a number one supplier of worldwide business providers to the life science business, at present introduced the launch of wave 1 of an revolutionary social media marketing campaign to achieve sufferers straight with training about diabetic gastroparesis (DGP). The preliminary wave of this program launched with two Facebook pages, a GimotiTM branded Facebook web page and a diabetic gastroparesis neighborhood Facebook web page known as DGP-n-Me: Diabetic Gastroparesis Support. The GIMOTI Facebook web page helps rising consciousness of GIMOTI as an essential nasal choice for sufferers who’re searching for reduction of their acute and recurrent signs of diabetic gastroparesis, particularly in circumstances the place oral therapies should not efficient. DGP-n-Me is a neighborhood devoted to providing help, training, and recommendation to individuals residing with signs of diabetic gastroparesis. Up to 16 million individuals within the U.S. undergo from signs of gastroparesis. The DGP-n-Me Facebook web page discovered right here permits neighborhood members to attach with one another and discover details about managing diabetic gastroparesis. Patients with DGP usually undergo signs for years earlier than they’ve a confirmatory analysis which frequently takes 5 years. During the time that they’re searching for solutions about what’s inflicting their signs, and even put up analysis, sufferers obtain little or no instructional help from the medical neighborhood concerning the illness, out there remedies and methods to handle their signs. “The DGP-n-me marketing campaign is devoted to filling that vital hole and offering sufferers a spot the place they’ll depend on curated content material, neighborhood and compassion. We’d prefer it to be a spot the place we will Empower the Patients Journey,” stated Chris Quesenberry, Gimoti Chief Commercial Officer. Gimoti is the primary and solely FDA-approved nasal supply therapy of metoclopramide for the reduction of signs in adults with acute and recurrent diabetic gastroparesis. People experiencing signs of diabetic gastroparesis and treating physicians can go to the Gimoti Facebook web page right here to be taught extra about its therapy advantages and security data. “We are happy to announce the launch of this revolutionary patient-centered marketing campaign. People affected by DGP usually resort to looking out on-line for solutions and Evoke intends to play a task in serving to convey extra data and help to those sufferers in want. In the method, we hope to assist increase consciousness of the illness and its burden on sufferers in addition to our novel nasal supply therapy choice that will provide profit the place oral drugs are sometimes unable to be absorbed,” commented Matt D’Onofrio, Evoke Pharma Chief Business Officer. The Facebook pages in reference can be accessed by clicking on the beneath: https://www.fb.com/Gimoti-metoclopramide-nasal-spray-104672345100289/ https://www.fb.com/DGPnMe/ About Gimoti™ (metoclopramide) nasal spray GIMOTI is indicated for the reduction of signs in adults with acute and recurrent diabetic gastroparesis. Important Safety Information BOXED WARNING: TARDIVE DYSKINESIA•        Metoclopramide could cause tardive dyskinesia (TD), a critical motion dysfunction that’s usually irreversible. The danger of growing TD will increase with period of therapy and whole cumulative dosage.•        Discontinue GIMOTI in sufferers who develop indicators or signs of TD. In some sufferers, signs might reduce or resolve after metoclopramide is stopped.•        Avoid therapy with metoclopramide (all dosage types and routes of administration) for longer than 12 weeks due to the elevated danger of growing TD with longer-term use. GIMOTI isn’t advisable for use in:•        Pediatric sufferers as a result of danger of growing tardive dyskinesia (TD) and different extrapyramidal signs in addition to the chance of methemoglobinemia in neonates.•        Moderate or extreme hepatic impairment (Child-Pugh B or C), average or extreme renal impairment (creatinine clearance lower than 60 mL/minute), and sufferers concurrently utilizing sturdy CYP2D6 inhibitors as a result of danger of elevated drug publicity and opposed reactions. GIMOTI is contraindicated:•        In sufferers with a historical past of tardive dyskinesia (TD) or a dystonic response to metoclopramide.•        When stimulation of gastrointestinal motility is perhaps harmful (e.g., within the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation).•        In sufferers with pheochromocytoma or different catecholamine-releasing paragangliomas. Metoclopramide might trigger a hypertensive/pheochromocytoma disaster, in all probability as a consequence of launch of catecholamines from the tumor.•        In sufferers with epilepsy. Metoclopramide might enhance the frequency and severity of seizures.•        In sufferers with hypersensitivity to metoclopramide. Reactions have included laryngeal and glossal angioedema and bronchospasm. Potential opposed reactions related to metoclopramide embody: Tardive dyskinesia (TD), different extrapyramidal results (EPS), parkinsonism signs, motor restlessness, neuroleptic malignant syndrome (NMS), despair, suicidal ideation and suicide, hypertension, fluid retention, hyperprolactinemia, results on the power to drive and function equipment. Most widespread opposed reactions (≥5% of sufferers in scientific research) for GIMOTI had been dysgeusia, headache, and fatigue. These should not all the potential uncomfortable side effects of GIMOTI. This data mustn’t take the place of you speaking along with your physician or healthcare skilled. If you’ve gotten any questions on your situation, or if you want extra details about GIMOTI, discuss to your physician or pharmacist. Only you and your healthcare skilled can resolve if GIMOTI is correct for you. You report uncomfortable side effects associated to Evoke Pharma merchandise by calling 1-833-4-GIMOTI (1-833-444-6684) or emailing [email protected]. If you like to report these to the FDA, both go to www.FDA.gov/medwatch or name 1-800-FDA-1088. About Evoke Pharma, Inc. Evoke is a specialty pharmaceutical firm centered totally on the event of medication to deal with GI issues and illnesses. The Company developed GIMOTI, a nasal spray formulation of metoclopramide, for the reduction of signs related to acute and recurrent diabetic gastroparesis in adults. Diabetic gastroparesis is a GI dysfunction affecting tens of millions of sufferers worldwide, by which the abdomen takes too lengthy to empty its contents leading to critical GI signs in addition to different systemic issues. The gastric delay attributable to gastroparesis can compromise absorption of orally administered drugs. Prior to FDA approval to commercially market GIMOTI, metoclopramide was solely out there in oral and injectable formulations and stays the one drug at the moment accredited within the United States to deal with gastroparesis. Visit www.EvokePharma.com for extra data. About EVERSANA Life Science Services, LLC EVERSANA™ is a number one supplier of worldwide providers to the life science business. The firm’s built-in options are rooted within the affected person expertise and span all phases of the product lifecycle to ship long-term, sustainable worth for sufferers, prescribers, channel companions and payers. The firm serves greater than 500 organizations, together with revolutionary start-ups and established pharmaceutical firms to advance life science options for a more healthy world. To be taught extra about EVERSANA, go to eversana.com or join by LinkedIn and Twitter. Safe Harbor Statement Evoke cautions you that statements included on this press launch that aren’t an outline of historic details are forward-looking statements. In some circumstances, you may determine forward-looking statements by phrases akin to “might,” “will,” “ought to,” “anticipate,” “plan,” “anticipate,” “might,” “intend,” “goal,” “challenge,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “proceed” or the negatives of those phrases or different comparable expressions. These statements are primarily based on Evoke’s present beliefs and expectations. These forward-looking statements embody statements relating to Evoke’s expectations on the social media advertising marketing campaign. The inclusion of forward-looking statements shouldn’t be thought to be a illustration by Evoke that any of its plans will probably be achieved. Actual outcomes might differ from these set forth on this press launch as a result of dangers and uncertainties related Evoke’s capacity to acquire and market and help GIMOTI and different dangers and uncertainties inherent in Evoke’s enterprise, together with these described in Evoke’s periodic filings with the SEC. You are cautioned to not place undue reliance on these forward-looking statements, which converse solely as of the date hereof, and Evoke undertakes no obligation to revise or replace this press launch to mirror occasions or circumstances after the date hereof. All forward-looking statements are certified of their entirety by this cautionary assertion. This warning is made underneath the protected harbor provisions of the Private Securities Litigation Reform Act of 1995. Investor Contacts: The Ruth GroupChristine Petraglia / James SaliernoTel: 917-633-8980 / [email protected] / [email protected] Media Contact: The Ruth GroupAnnika ParrishTel: [email protected]